• Danylo Rafhael Costa-Silva, Maria da Conceição Barros-Oliveira, Francisco Adelton Alves-Ribeiro, Larysse Cardoso Campos-Verdes, Elmo de Jesus Nery Junior, Samara Fernanda Vieira-Valença, Rodrigo Jose de Vasconcelos-Valença, Veronica Mendes Soares, André Luiz Pinho-Sobral, Emerson Brandão Sousa, Pedro Vitor Lopes-Costa, Dos Santos Alesse Ribeiro AR Getulio Vargas Hospital, Federal University of Piaui, Teresina, Piaui., Jackeline Lopes Viana, Arquimedes Cavalcante Cardoso, Victoria Maria Luz-Borges, Renato de Oliveira Pereira, Cleciton Braga Tavares, Vladimir Costa Silva, Dorival Mendes Rodrigues-Junior, Luiz Henrique Gebrim, and da Silva Benedito Borges BB 0000-0002-9542-7538 Department of Health, Northeast, Postgraduate Program of the Northeast Network of Biotechnology (RENOR.
• Department of Health, Northeast, Postgraduate Program of the Northeast Network of Biotechnology (RENORBIO).
• Medicine (Baltimore). 2020 Oct 23; 99 (43): e22890.

AbstractBreast cancer is the most common malignancy affecting women worldwide. The insulin-like growth factor 1 (IGF-1) gene encodes a protein responsible for a wide variety of physiological processes, including differentiation and cell proliferation. Despite several studies on tumor tissues, no study has evaluated IGF-1 expression in the peripheral blood of women with recurrent breast cancer.In this cross-sectional study, IGF-1 expression in the peripheral blood of 146 women with breast cancer treated approximately 5 years ago was quantified by quantitative reverse transcription polymerase chain. The women were divided into 2 groups: non-recurrence (n = 85) and recurrence (n = 61). Statistical analysis of the data was performed using ANOVA, Mann-Whitney, and Chi-squared tests (P < .05).The results showed no significant difference in IGF-1 expression between the non-recurrence and recurrence groups (P = .988). In the subgroups of patients with lymph node involvement, no statistically significant difference was observed in IGF-1 expression between women with recurrence and those non-recurrence (P = .113). In patients without lymph node metastases, IGF-1 messenger ribonucleic acid (mRNA) expression levels were significantly higher in the non-recurrence group than in the recurrence group (P = .019). Furthermore, using the median IGF-1 mRNA expression as the cutoff point, it was obtained a statistically significant difference in tumor histological grade among women with recurrent breast cancer (P = .042).These data showed significantly higher IGF-1 expression in women without lymph node metastases in the non-recurrence group compared with the recurrence group. In addition, a significant difference was observed in median IGF-1 mRNA expression in relation to tumor histological grade in women with recurrent breast cancer.

38 keywords...

hide…